DK0885888T3 - Isoquinolinderivater og lægemidler - Google Patents
Isoquinolinderivater og lægemidlerInfo
- Publication number
- DK0885888T3 DK0885888T3 DK97901806T DK97901806T DK0885888T3 DK 0885888 T3 DK0885888 T3 DK 0885888T3 DK 97901806 T DK97901806 T DK 97901806T DK 97901806 T DK97901806 T DK 97901806T DK 0885888 T3 DK0885888 T3 DK 0885888T3
- Authority
- DK
- Denmark
- Prior art keywords
- hydroxy
- halogen
- compound
- amino group
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 abstract 1
- 206010047163 Vasospasm Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1794696 | 1996-02-02 | ||
| JP27588696 | 1996-10-18 | ||
| PCT/JP1997/000240 WO1997028130A1 (fr) | 1996-02-02 | 1997-01-31 | Derives de l'isoquinoline et medicaments associes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0885888T3 true DK0885888T3 (da) | 2003-11-24 |
Family
ID=26354541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97901806T DK0885888T3 (da) | 1996-02-02 | 1997-01-31 | Isoquinolinderivater og lægemidler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6153608A (fr) |
| EP (1) | EP0885888B1 (fr) |
| JP (1) | JP3834663B2 (fr) |
| KR (1) | KR19990082174A (fr) |
| CN (1) | CN1210521A (fr) |
| AT (1) | ATE247090T1 (fr) |
| AU (1) | AU1557497A (fr) |
| DE (1) | DE69724108T2 (fr) |
| DK (1) | DK0885888T3 (fr) |
| ES (1) | ES2205166T3 (fr) |
| PT (1) | PT885888E (fr) |
| WO (1) | WO1997028130A1 (fr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1023269A4 (fr) * | 1997-09-30 | 2001-06-27 | Molecular Design Int | Agonistes de beta3-adrenorecepteurs, compositions d'agonistes et procedes d'utilisation |
| AU9646198A (en) * | 1997-10-22 | 1999-05-10 | Nippon Shinyaku Co. Ltd. | Isoquinoline derivative and drug |
| JP4212149B2 (ja) * | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 医薬 |
| CN100444843C (zh) * | 1998-08-10 | 2008-12-24 | 旭化成制药株式会社 | 法舒地尔盐酸盐缓释口服制剂 |
| EP1177796B1 (fr) | 1999-04-27 | 2011-04-27 | Mitsubishi Tanabe Pharma Corporation | Médicament pour la prévention ou le traitement des maladies du foie |
| US6593341B2 (en) | 2001-03-29 | 2003-07-15 | Molecular Design International, Inc. | β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
| US7109208B2 (en) * | 2001-04-11 | 2006-09-19 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents |
| WO2003024457A1 (fr) * | 2001-09-11 | 2003-03-27 | Asahi Kasei Kabushiki Kaisha | Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie |
| DE10153605A1 (de) * | 2001-11-02 | 2003-05-28 | Morphochem Ag Komb Chemie | Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens |
| WO2003082279A1 (fr) * | 2002-03-28 | 2003-10-09 | Teijin Limited | Preparation solide contenant une forme monocristalline |
| US7094789B2 (en) * | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
| US6596734B1 (en) | 2002-10-11 | 2003-07-22 | Molecular Design International, Inc. | Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists |
| US7160894B2 (en) | 2003-06-06 | 2007-01-09 | Asahi Kasei Pharma Corporation | Tricyclic compound |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| MXPA06006980A (es) * | 2003-12-22 | 2006-12-14 | Alcon Inc | Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica. |
| CA2548146A1 (fr) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents pour le traitement de la retinopathie diabetique et la formation de corps colloides dans la degeneration maculaire |
| JP4854070B2 (ja) * | 2004-01-29 | 2012-01-11 | 旭化成ファーマ株式会社 | バイパス術に伴う血管攣縮治療剤 |
| US20060115870A1 (en) * | 2004-03-30 | 2006-06-01 | Alcon, Inc. | High throughput assay for human Rho kinase activity |
| US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
| US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| PE20060481A1 (es) * | 2004-06-30 | 2006-06-19 | Schering Corp | N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas |
| US20060247266A1 (en) * | 2004-11-26 | 2006-11-02 | Asahi Kasei Pharma Corporation | Nitrogen-containing tricyclic compounds |
| MY139797A (en) * | 2004-11-29 | 2009-10-30 | Kowa Co | (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate |
| DE602006021704D1 (de) | 2005-02-25 | 2011-06-16 | Kowa Co | Verfahren zur herstellung eines 4-fluorisochinolin-5-sulfonylhalogenids oder eines salzes davon |
| WO2006115247A1 (fr) * | 2005-04-25 | 2006-11-02 | D. Western Therapeutics Institute, Inc. | INHIBITEUR HAUTEMENT SELECTIF DE LA Rho-KINASE |
| WO2006115244A1 (fr) * | 2005-04-25 | 2006-11-02 | D. Western Therapeutics Institute, Inc. | Dérivé de 4-bromoisoquinoléine et préparation pharmaceutique comprenant celui-ci |
| WO2006115245A1 (fr) * | 2005-04-25 | 2006-11-02 | D. Western Therapeutics Institute, Inc. | Dérivé de 4-éthynylisoquinoléine et préparation pharmaceutique comprenant celui-ci |
| CA2621181C (fr) | 2005-08-30 | 2011-04-19 | Asahi Kasei Pharma Corporation | Composes de 5-isoquinolinesulfonamide |
| EP2049110B1 (fr) * | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Diazépans pontés antagonistes du récepteur de l'oréxine |
| US20080064681A1 (en) * | 2006-09-11 | 2008-03-13 | Hiroyoshi Hidaka | Therapeutic agent for treating glaucoma |
| WO2008089351A1 (fr) * | 2007-01-17 | 2008-07-24 | Wisconsin Alumni Research Foundation | Culture améliorée de cellules souches |
| US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| AU2008220104B2 (en) | 2007-02-28 | 2012-09-27 | Asahi Kasei Pharma Corporation | Sulfonamide derivative |
| ES2396795T3 (es) | 2007-07-02 | 2013-02-27 | Asahi Kasei Pharma Corporation | Compuesto de sulfonamida y cirstal del mismo |
| WO2010028011A1 (fr) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides de diazabicyclononanes et leurs utilisations |
| CN101429191B (zh) * | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| CN101386617B (zh) * | 2008-11-03 | 2012-06-13 | 中国药科大学 | 取代的四氢异喹啉衍生物、其制备方法及含有它们的药物组合物 |
| US8933071B2 (en) * | 2008-11-07 | 2015-01-13 | Northwestern University | Dimethyl fasudil for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders |
| BRPI1011683B8 (pt) | 2009-06-19 | 2021-05-25 | D Western Therapeutics Inst Inc | derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos |
| WO2011021221A2 (fr) | 2009-08-17 | 2011-02-24 | Reliance Life Sciences Pvt. Ltd. | Compositions destinées aux lésions de la moelle épinière |
| WO2012026529A1 (fr) | 2010-08-26 | 2012-03-01 | 興和株式会社 | Nouveau procédé de production de dérivés isoquinoline et de leurs sels |
| CN105085478B (zh) * | 2014-04-28 | 2019-04-12 | 南京明德新药研发股份有限公司 | 异喹啉磺胺衍生物及其药物组合物和制药用途 |
| CN105085525B (zh) * | 2014-04-28 | 2019-01-04 | 南京明德新药研发股份有限公司 | 作为rho激酶抑制剂的异喹啉磺酰衍生物 |
| ES2774923T3 (es) * | 2014-04-28 | 2020-07-23 | China Resources Pharmaceutical Holdings Company Ltd | Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa |
| JP6755775B2 (ja) * | 2016-11-04 | 2020-09-16 | 富士アミドケミカル株式会社 | ４−フルオロイソキノリンの製法 |
| CN109134433B (zh) * | 2017-06-16 | 2021-05-25 | 成都先导药物开发股份有限公司 | 一种抑制rock的化合物及其应用 |
| ES2927542T3 (es) * | 2017-07-19 | 2022-11-08 | China Resources Pharmaceutical Holdings Company Ltd | Derivado de isoquinolinilsulfonilo y uso del mismo |
| CN111132983B (zh) * | 2017-09-25 | 2022-05-17 | 华润医药控股有限公司 | 一种异喹啉磺酰衍生物的晶型及其制备方法 |
| CN111116555B (zh) | 2018-10-30 | 2023-06-02 | 北京盈科瑞创新药物研究有限公司 | 一种Rho激酶抑制剂及其制备方法和应用 |
| CN111440150B (zh) * | 2020-05-12 | 2021-04-06 | 中国药科大学 | 一种一氧化氮供体型法舒地尔衍生物及其制备方法和用途 |
| EP4422626A1 (fr) | 2021-10-30 | 2024-09-04 | Aneuryst, Inc | Traitements d'un dérèglement de l'homéostasie cérébrale |
| CN115626925A (zh) * | 2022-12-08 | 2023-01-20 | 山东汇海医药化工有限公司 | 一种双哌啶的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0227992B2 (ja) * | 1982-01-14 | 1990-06-20 | Asahi Kasei Kogyo Kk | Isokinorinsuruhonirukagobutsu |
| JPS57156463A (en) * | 1981-03-20 | 1982-09-27 | Asahi Chem Ind Co Ltd | Isoquinoline derivative |
| US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| JPS5993054A (ja) * | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| JPS61152658A (ja) * | 1984-12-27 | 1986-07-11 | Asahi Chem Ind Co Ltd | 置換されたイソキノリンスルホンアミド誘導体 |
| JPS61227581A (ja) * | 1985-04-02 | 1986-10-09 | Asahi Chem Ind Co Ltd | 血管拡張剤 |
| JP2720348B2 (ja) * | 1989-03-30 | 1998-03-04 | 旭化成工業株式会社 | 脳細胞機能障害改善剤 |
-
1997
- 1997-01-31 ES ES97901806T patent/ES2205166T3/es not_active Expired - Lifetime
- 1997-01-31 AT AT97901806T patent/ATE247090T1/de active
- 1997-01-31 DK DK97901806T patent/DK0885888T3/da active
- 1997-01-31 CN CN97191967A patent/CN1210521A/zh active Pending
- 1997-01-31 KR KR1019980705899A patent/KR19990082174A/ko not_active Withdrawn
- 1997-01-31 DE DE69724108T patent/DE69724108T2/de not_active Expired - Lifetime
- 1997-01-31 PT PT97901806T patent/PT885888E/pt unknown
- 1997-01-31 AU AU15574/97A patent/AU1557497A/en not_active Abandoned
- 1997-01-31 WO PCT/JP1997/000240 patent/WO1997028130A1/fr not_active Ceased
- 1997-01-31 US US09/117,433 patent/US6153608A/en not_active Expired - Lifetime
- 1997-01-31 JP JP51067397A patent/JP3834663B2/ja not_active Expired - Lifetime
- 1997-01-31 EP EP97901806A patent/EP0885888B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6153608A (en) | 2000-11-28 |
| AU1557497A (en) | 1997-08-22 |
| PT885888E (pt) | 2003-12-31 |
| EP0885888A1 (fr) | 1998-12-23 |
| EP0885888A4 (fr) | 2000-07-19 |
| DE69724108D1 (de) | 2003-09-18 |
| WO1997028130A1 (fr) | 1997-08-07 |
| CN1210521A (zh) | 1999-03-10 |
| JP3834663B2 (ja) | 2006-10-18 |
| EP0885888B1 (fr) | 2003-08-13 |
| ATE247090T1 (de) | 2003-08-15 |
| DE69724108T2 (de) | 2004-06-09 |
| KR19990082174A (ko) | 1999-11-25 |
| ES2205166T3 (es) | 2004-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0885888T3 (da) | Isoquinolinderivater og lægemidler | |
| GC0000375A (en) | Benzodiazepine derivatives as gaba a receptor modulators | |
| BG106586A (en) | Pyrazolopyramidines as therapeutic agents | |
| DE69529614D1 (de) | Heterobizyklische derivate | |
| DK1065204T3 (da) | Bicykliske carbonyl-indolforbindelser som anti-inflammatoriske/analgesiske midler og som COX-2-inhibitorer | |
| MY136270A (en) | Processes and intermediates for preparing anti-cancer compounds | |
| CY1109558T1 (el) | Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων | |
| DE60000611D1 (en) | 4-oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamide als antivirale mittel | |
| IS6565A (is) | Trópan afleiður nytsamlegar í meðferð | |
| NZ514095A (en) | Amide compounds and medicinal use thereof | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| DK0870768T3 (da) | Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler | |
| DK1543010T3 (da) | N-substituerede hydromorphoner og anvendelse deraf | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| IL138645A0 (en) | Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways | |
| BR0105563A (pt) | Derivados e análogos de galantamina | |
| NZ334896A (en) | Benzo[de]isoquinoline-1,3-diones for inhibiting bacterial DNA gyrase and DNA topoisomerase | |
| DE69828197D1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
| MXPA03004023A (es) | Compuestos quimicos. | |
| AU2002214320A1 (en) | Imidazole derivatives, process for their preparation and their use | |
| EP1110960A4 (fr) | Agents induisant l'apoptose | |
| CA2245728A1 (fr) | Derives de l'isoquinoline et medicaments associes | |
| ES2012958A6 (es) | Procedimiento para preparar derivados de cisteina. | |
| PL329885A1 (en) | Derivatives of polyhydroxyphenol and agents containing them for use in prophylactics and treatment of bone and cartilage diseases | |
| WO2000002519A3 (fr) | Utilisation de derives de tetrahydropyridines (ou 4-hydroxypiperidines)-butylazoles dans l'elaboration d'un medicament pour le traitement de la douleur |